Becker Private Equity & Business Podcast

Episode: Trends in Physician Practice Management and Urology Investments

Date: August 28, 2025
Host: Scott Becker
Guest: Amber Walsh, Executive Committee Member, McGuireWoods LLP

Episode Overview

This episode explores current trends in physician practice management (PPM), with a particular focus on private equity investments in urology practices. Host Scott Becker speaks with Amber Walsh, who provides insights into the state of PPM deals, the unique characteristics that make urology a resilient and attractive specialty for investors, current "hot" areas within urology, and other specialties seeing activity. The discussion touches on market caution due to economic and regulatory factors, as well as the evolution of practice integration and ancillary revenue streams.

Key Discussion Points & Insights

1. Market Trends in Physician Practice Management

• Increased Caution in Deal-Making (00:33):
  Amber observes that over the last 18 months there’s been “more intensive regulatory scrutiny” and a “deeper dive into really the most attractive investment opportunities.”
• Impact of Economic Climate (01:10):
  The boom years of 2020–2022 have given way to a market environment marked by caution from both “private equity investors and debt investors.”
• Q2 2025 Data (01:52):
  • Deals are ongoing, but there are “fewer” and they “take a little bit longer to get done.”
  • Primary drivers: “state level transactional review processes” and “economic uncertainty.”
• Consistency of Trend (02:16):
  The careful approach has been a “pretty consistent theme over the past 18 months, possibly even as long as two years.”

2. Why Urology Remains Resilient

• Resilience and Recession Resistance (02:55):
  Urology is described as “a little bit more recession proof than some other specialties,” with most procedures being “long established” and often not elective.

• Diverse Revenue Streams (03:28):

  • Ancillary services within urology practices: “ASC investments, pathology, independent pharmacy dispensing, infusions, diagnostics, genitourinary cancer treatments, clinical research, and radiation therapy.”
  • These integrations offer “opportunity for care, better care, but also ways to save money for the health care system.”

• Investment Rationale (04:55):
  Urology practices present “a lot of opportunity” and can be supported “through growth capital” by investors.

  Quote:
  “There’s just a lot of opportunity in urology practices that make it really interesting and something that an investor can look at and think they can really help to support through growth capital.”
  — Amber Walsh [04:55]

3. Hot Investment Areas Within Urology

• Oncology and Ancillary Revenue (05:55):

  • Oncology treatments, clinical research, and in-house pharmacy dispensing are areas of high focus.
  • Quoting Amber:
    “Clinical research and that independent pharmacy dispensing… both bring revenue into the practice, but also increase accessibility for the patient.”
    — [05:59]

• Market Drivers (06:20):

  • “Staggering number” of genitourinary cancer diagnoses each year is a major market driver.
  • Demographics: An aging population, with “10,000 people turning 65 every day in the United States.”

• Structures and Scale (06:53):

  • Presence of large specialty groups (e.g., United Urology) and the role of private equity MSOs.
  • Integration into multi-specialty oncology platforms.

  Quote:
  “It’s been kind of an interesting way to see different builds and growth in urology.”
  — Amber Walsh [07:41]

4. Other Active Specialties

• Orthopedics and Women’s Health (08:00):
  Several orthopedic deals and some women’s health transactions announced in Q2.
• Elective/Cosmetic Caution (08:12):
  Less activity in “purely electives” such as cosmetics and some dermatology practices, reflecting economic caution.
• General Outlook (08:28):
  “You still see some interest in those areas too. So I don’t think anything is really off the table. It’s just… there’s more discernment.”

Notable Quotes & Memorable Moments

On deal caution and regulatory scrutiny:

“…much more kind of deep diving into really the most attractive investment opportunities. There’s been more…caution maybe for private equity investors and debt investors when looking at PPM investments than there had been in the super boom of 2020 through 2022.”
— Amber Walsh [00:42]

On urology’s resilience:

“Generally speaking, most of the procedures are long established…not considered to be elective or even things that can really be put off. And there’s a lot of ancillary services that are natural extensions of the physician’s own personal services.”
— Amber Walsh [03:10]

On areas of profitability:

“A lot of the oncology treatments is a big focus. But I think the clinical research and that independent pharmacy dispensing opportunities within the practice…those are things that…a lot of practices look at as opportunities to both bring revenue into the practice, but also increase accessibility for the patient.”
— Amber Walsh [05:56]

On discernment in specialty investments:

“It’s just a period of time when there’s more discernment is what I would say.”
— Amber Walsh [08:39]

Important Timestamps

• 00:33 — Amber Walsh on increased regulatory scrutiny and overall caution in PPM.
• 02:55 — Why urology remains resilient and attractive for investors.
• 05:55 — “Hottest” areas in urology: oncology, clinical research, independent pharmacy.
• 08:00 — Other specialties seeing investment: orthopedics, women’s health.
• 08:39 — Current climate: “more discernment” rather than blanket enthusiasm.

Summary

This episode delivers a timely, expert overview of physician practice management trends, placing a spotlight on urology as a specialty with unique resilience and multiple integrated revenue opportunities. Amber Walsh details the shift toward heightened caution and regulatory review, the diversification within urology practices, and what makes certain ancillary services especially attractive. Listeners gain insights into the broader deal environment, as well as where private equity is focusing attention within and beyond urology today.